argenx is a biotechnology company developing antibody-based treatments for severe autoimmune diseases. Its commercial franchise centers on VYVGART, which targets the neonatal Fc receptor to reduce pathogenic IgG antibodies in conditions including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company is pursuing additional indications and immune-mediated diseases using its antibody engineering capabilities.
argenx SE ADR (ARGX) has a MarketKingdoms composite score of 68.0 (B), an B-range rating. It ranks 510th of 1,866 covered companies, 22nd of 78 in Healthcare (sector average 64.4) and 5th of 12 in Biotechnology. Scores as of 2026-10-26.
Its strongest lenses are Expansion (growth) at 92 (Healthcare average 50) and Stock selection at 80 (Healthcare average 79). Its weakest lenses are Price (valuation) at 28 (sector average 50) and Trend (momentum) at 35 (sector average 50).
| Lens | Type | ARGX | Healthcare average | Biotechnology average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 80 | 79 | 78 | 54th |
| KPI momentum | Research signal | 78 | 78 | 75 | 48th |
| Catalyst watch | Research signal | 75 | 74 | 74 | 56th |
| Price (valuation) | Fundamental lens | 28 | 50 | 30 | 22nd |
| Expansion (growth) | Fundamental lens | 92 | 50 | 64 | 95th |
| Quality (profitability) | Fundamental lens | 80 | 50 | 55 | 94th |
| Trend (momentum) | Fundamental lens | 35 | 50 | 48 | 28th |
The most recent call analysed was held on 2026-10-22 (fiscal 2026 Q3). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -27.3%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 0.18, sector beta -0.27, industry beta 0.46; the factor model explains 14% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 74.9 | B+ | -17.8% |
| BeOne Medicines Ltd ADR (ONC) | 73.4 | B+ | -26.6% |
| Regeneron Pharmaceuticals Inc. (REGN) | 72.7 | B+ | +7.7% |
| Vertex Pharmaceuticals Incorporated (VRTX) | 68.1 | B | -7.5% |
| Incyte Corporation (INCY) | 68.0 | B | -18.8% |
| Alnylam Pharmaceuticals Inc. (ALNY) | 61.4 | B- | -18.1% |
| Bio-Techne Corporation (TECH) | 60.4 | B- | -22.2% |
| Insmed Inc. (INSM) | 60.0 | B- | -48.5% |
argenx SE ADR financial statements · Healthcare sector ranking · Biotechnology industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.